A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a first-line breast cancer trial, the companies have scored again in another ...

Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced the launch of Project EVEREST—a groundbreaking ...

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for their TROP2-directed antibody-drug conjugate (ADC) for breast cancer, Datroway, the latest to emerge from ...

Daiichi Sankyo. “With the results of DESTINY-Breast09 and DESTINY-Gastric04, we now have six breast and two gastric cancer randomized trials that have demonstrated significant survival ...

Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings The PFS improvement was seen across all pre-specified patient subgroups ...

Daiichi Sankyo is confident Enhertu can top Roche’s ADC, and also expand the use of HER2 drugs into new cancers like HER2-positive gastric cancer – an indication that is under review by the ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for use in certain cases of pre-treated breast cancer. The drug has been ...

THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial ... directed DXd antibody-drug conjugate (ADC) discovered by Daiichi Sankyo DSNKY DSKYF and being jointly developed and ...